Accrol announces the second grant of options to executive Directors and certain senior management under its Long Term Incentive Plan; options over 7,967,183 shares in aggregate were granted under the LTIP

Sample article from our Tissue & Hygiene

February 24, 2022 (press release) –

Accrol (AIM: ACRL), the UK's leading independent tissue converter, announces the second grant of options to executive Directors and certain senior management under the Long Term Incentive Plan ("LTIP") announced on 5 March 2021.

 

The LTIP was established to incentivise management to deliver long-term value creation for shareholders and ensure alignment with shareholder interests.

 

Background

 

The LTIP is based on market standard annual awards and is limited to a maximum of 5% of the issued share capital of the Company over its five year life.

 

All awards made under the LTIP will be made by the granting of nil-cost options established in accordance with the rules of the LTIP and vesting is subject to adjusted EBITDA targets in line with the LTIP rules.

 

The Remuneration Committee has discretion to amend these terms to take account of, for example, corporate activities such as acquisitions to ensure that the performance targets remain appropriate. Malus and clawback provisions are also in place to reduce or recover any awards for criteria such as any material misstatement of the financial statements, a serious breach of the Company's code of ethics or a serious health and safety issue.

 

Award size, performance conditions and dilution

 

On 23 February 2022, options over 7,967,183 shares in aggregate (the "2022 Awards") were granted under the LTIP, including those set out below which were granted to directors and other persons discharging managerial responsibility:

 

Director / PDMR

Role

Number of shares over which 2022 Awards made

Dan Wright

Executive Chairman

1,197,391

Gareth Jenkins

Chief Executive Officer

2,494,565

Richard Newman

Chief Financial Officer

1,341,522

 

The 2022 Awards are subject to the below Adjusted EBITDA targets measured over the performance period ending on 30 April 2024 and are summarised below:

 

Adjusted EBITDA for FY2024

Percentage of the 2022 Award that may vest

Less than £18.0m

0%

Between £18.0m and £20.0m

between 25% and 100%

£20.0m or greater

100%

 

If the maximum targets are met in FY24, the total dilutive impact of the 2022 Awards will be c.2.5%. The maximum aggregate dilutive effect of awards then issued under the LTIP will stand at 3.5% of issued share capital. 

 

 

For further information, please contact:

 

 

 

Accrol Group Holdings plc

 

Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer

 

 

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King

Tel: +44 (0) 203 829 5000

 

 

Liberum Capital Limited (Joint Broker)

Tel: +44 (0) 20 3100 2222

Clayton Bush / Edward Thomas

 

 

 

Belvedere Communications Limited

 

Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525

Llew Angus

Tel:  +44 (0) 7407 023 147

 

accrolpr@belvederepr.com

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls and facial tissues to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisition of a state-of-the-art tissue converter based in Leicester, the Group now operates from six sites, including four in Lancashire, which generate revenues totalling c.16% of the £2.0bn UK retail tissue market.

 

 

The below information and notification is made in accordance with the EU Market Abuse Regulation.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING  MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM


1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dan Wright

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001 each

 

 

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Grant of options over ordinary shares under the Company's new LTIP
 

c)

Price(s) and volume(s)

a)     Volume: 1,197,391
Price :  £0.001
 

d)

Aggregated information

- Aggregated volume

- Price

 

a)     Price :  £0.001
Volume: 1,197,391

e)

Date of the transaction

a)     23 Feb 2022

 

f)

Place of the transaction

a)     Off market transaction
 

 

 


1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Gareth Jenkins

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001 each

 

 

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Grant of options over ordinary shares under the Company's new LTIP
 

c)

Price(s) and volume(s)

a)     Volume: 2,494,565
Price :  £0.001
 

d)

Aggregated information

- Aggregated volume

- Price

 

a)     Price :  £0.001
Volume: 2,494,565

e)

Date of the transaction

a)     23 Feb 2022

 

f)

Place of the transaction

a)     Off market transaction
 

 


1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Richard Newman

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001 each

 

 

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Grant of options over ordinary shares under the Company's new LTIP
 

c)

Price(s) and volume(s)

a)     Volume: 1,341,522
Price :  £0.001
 

d)

Aggregated information

- Aggregated volume

- Price

 

a)     Price :  £0.001
Volume: 1,341,522

e)

Date of the transaction

a)     23 Feb 2022

 

f)

Place of the transaction

a)     Off market transaction
 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our Tissue & Hygiene Coverage
See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.